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Abstract 
Renal cysts are a common radiological finding in adults and children. They occur in a 
variety of conditions and the clinical presentation, management and prognosis varies 
widely. In this article, we discuss the major causes of renal cysts in children and 
adults with a particular focus on the most common genetic forms. Many cystoproteins 
have been localised to the cilia centrosome complex (CCC). We discuss the evidence 
for a universal ‘cilia hypothesis’ for cyst formation and the evidence for non-ciliary 
proteins in cyst formation. 
 
Introduction 
Renal cystic diseases comprise one of the most common genetic causes of kidney 
disease in man. As a group, they are however remarkably heterogenous and may 
present as part of rare syndromes. Autosomal dominant polycystic kidney disease 
(ADPKD) is the most common inherited cause of end-stage renal disease (ESRD) in 
adults and accounts for 10% of all ESRD. Nephronopthisis, an autosomal recessive 
condition is the most common inherited cause of ESRD in children. In this article, we 
summarise the major genetic causes of cystic disease in children and adults. Due to 
space considerations, non-genetic and syndromic causes are only mentioned in brief 
but should be borne in mind as part of the differential diagnosis (Table 1). 
 
Autosomal Recessive Polycystic Kidney Disease (ARPKD) 
Autosomal recessive polycystic kidney disease (ARPKD) is caused by mutations in a 
single gene, PKHD1. The incidence is 1 in 20,000 live births and the gene frequency 
is 1 in 70. Over 300 mutations have been identified and genotype-phenotype 
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correlations have been described [1] PKHD1 is located on chromosome 6p12 and 
encodes the protein fibrocystin/polyductin.[2, 3]  
 
Pathophysiology and Histopathology 
The exact function of fibrocystin is unknown. It is expressed on primary cilia and the 
cytoplasmic tail contains a ciliary targeting sequence.[4, 5] ARPKD is one of a 
number of conditions grouped together as ‘ciliopathies’[6]. Cystogenesis is probably 
caused by aberrant cell proliferation and apoptosis but it is still unclear how this is 
regulated. Down regulation of PKHD1 induces cell apoptosis [7]. Fibrocystin binds to 
and functionally interacts with the PKD2 protein, polycystin 2 [8, 9]. A genetic 
interaction between Pkd1 and Pkhd1 has been reported though no direct interaction 
was demonstrated between fibrocystin and the PKD1 protein, polycystin 1 [10]. 
 
Patients with ARPKD have diffuse dilatation and elongation of the renal collecting 
ducts. Cysts are usually small (<3mm) but as their number increases, the kidneys 
enlarge. At autopsy, there is poor corticomedullary differentiation due to the extension 
of the collecting ducts from the medulla to cortex. In foetuses and neonates, there is a 
correlation between genotype and the degree of collecting duct extension and cortical 
tubule lesions.[11] 
 
All patients with ARPKD have congenital hepatic fibrosis (CHF) or Caroli disease. 
The histological basis of CHF is a ductal plate malformation which consists of portal 
fibrosis, bile duct proliferation and hypoplasia of portal vein branches leading to 
portal hypertension [12]. The pathognomonic feature of Caroli disease is the presence 
of non-obstructive dilated intrahepatic bile ducts. 
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Clinical Presentation  
ARPKD affects males and females equally and can affect all racial groups. There is a 
wide spectrum in the age of presentation which correlates with disease severity. Those 
with the most severe phenotype present in the neonatal period with oligohydramnios, 
pulmonary hypoplasia and Potter facies. Although ARPKD has been classically 
reported in childhood or adolescence, mild or late onset disease can present in adult 
life, occasionally as isolated CHF [13]. In a single centre retrospective study, the 
actuarial renal survival of ARPKD children surviving the first month of life was 86% 
at one year [14]. Similarly, a second retrospective study showed that overall survival 
20 years after diagnosis depended largely on the age at presentation ie 36% (< 1yr), 
80% (1-20yrs) and 88% (>20yr) [13]. In a study of 164 neonatal survivors with 
ARPKD, the renal survival rates were 86% at 5 years, 71% at 10 years, and 42% at 20 
years [15]. Thus apart from severe neonatal presentation, overall survival is 
surprisingly good. 
 
Individuals may develop urinary concentrating defects and present with polyuria and 
polydipsia. Recurrent urinary tract infections (UTIs) may occur and hypertension is 
common, leading to cardiac hypertrophy and congestive cardiac failure in severe 
cases. Portal hypertension due to congenital hepatic fibrosis leading to splenomegaly 
and varices can be the presenting feature. Although hepatocellular function is usually 
preserved, ascending suppurative cholangitis can lead to hepatic failure [12]. 
Progression to end stage renal disease (ESRD) is common.  
 
Investigations 
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The diagnosis of ARPKD relies mainly on imaging. Ultrasound can make the 
diagnosis prenatally by showing bilaterally enlarged echogenic kidneys. In the 
neonate, ultrasound shows bilateral smooth enlarged kidneys which are diffusely 
echogenic with poor corticomedullary differentiation. The liver may also show an 
increase in parenchymal echogenicity. Studies have suggested that the kidney size 
stays stable or reduces with increasing age with increased echogenicity in the 
cortex.[16] There may be macrocysts in the liver and pancreas and splenomegaly. 
Portal hypertension is associated with reversal of hepatic blood flow detectable by 
Doppler ultrasound. 
 
Several studies have shown a clear genotype-phenotype correlation for ARPKD. In 
one study, the presence of a single truncating PKHD1 mutation was associated with 
death in the first month of life whereas the presence of a missense mutation was 
associated with survival beyond the first month. All patients inheriting two truncating 
mutations were uniformly associated with perinatal or neonatal death [17]. 
 
Mutation testing is now available with an overall detection rate of 77% [13, 15]. Most 
mutations are private and numerous polymorphisms have been reported in PKHD1. In 
European populations, T36M is the most common mutation reported (15-20%) and 
could represent a founder mutation [15]. Linkage analysis could be unreliable since 
other genes may phenocopy ARPKD.  
 
Treatment 
ARPKD is not curable. In the neonatal period, mechanical ventilation may be required 
for pulmonary hypoplasia or respiratory compromise due to enlarged kidneys. 
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Bilateral nephrectomy may be indicated. In anuric individuals, continuous veno-
venous haemofiltration (CVVH) or peritoneal dialysis can be used. Hypertension and 
urinary tract infections should be treated adequately. 
Hepatic complications are common. Bacterial cholangitis is serious and must be 
treated promptly. Oesophageal varices can be treated by sclerotherapy, banding or 
insertion of a porto-caval shunt. A final option is partial liver transplantation, 
sometimes combined with renal transplantation.[18] 
The mTOR pathway is activated in ARPKD kidneys suggesting that mTOR might be 
a potential target to slow cyst development.[19] In animal models of experimental 
polycystic kidney disease, mTOR inhibition was shown to reduce cyst growth and 
slow the loss of renal function.[20] (but see later). 
 
Prognosis 
Currently it is estimated that 23-30% of affected individuals die in the first year of 
life.[14, 15] For those that survive the first year of life, 10 year survival is estimated to 
be 82%.[15]. Significant intrafamilial variability has been reported in some families 
indicating the influence of modifying genes [17]. 
 
Autosomal Dominant Polycystic Kidney Disease 
Autosomal dominant polycystic kidney disease (ADPKD) is among the most common 
inherited diseases in man. Its prevalence is 1 in 400 to 1 in 1000. 85% of affected 
families have mutations in PKD1 (located on the short arm of chromosome 16) which 
encodes for Polycystin 1. The rest have mutations in PKD2 (located on the long arm 
of chromosome 4), which encodes for Polycystin 2. Some studies have proposed a 
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third gene but this has not been identified.[21, 22] Individuals with PKD2 mutations 
present later and have a slower rate of progression to ESRD than individuals with 
PKD1 mutations.[23] Transheterozygotes with mutations in both PKD1 and PKD2 
have been reported; their clinical course is more severe than for individuals with 
mutations in simple heterozygotes.[24] 
 
Pathophysiology and Histopathology 
Polycystin 1 and 2 form a functional receptor-channel complex and a defect in either 
protein leads to renal cyst formation and an overlapping clinical phenotype [25, 26]. 
Both proteins have overlapping subcellular distribution including in primary cilia [27, 
28]. However, polycystin-2 is mainly resident in the ER where it can function as a 
Ca2+ release channel. [25, 26] Unlike ARPKD, cysts can arise from any part of the 
nephron. Cysts arise as outpouchings connected to the tubular lumen which eventually 
disconnect. Over time, they enlarge, destroying normal parenchyma and result in 
bilateral kidney enlargement. 
 
Clinical Presentation  
Most patients present between 20-40 years of age but can present in childhood (early 
onset, under 15 years of age) or even in utero (very early onset, less than 2 years of 
age). Common renal symptoms include abdominal pain, polyuria, UTIs, haematuria 
and hypertension. Extra-renal features are rare in children. They include hepatic, 
pancreatic, ovarian, splenic and intestinal cysts. There is an increased prevalence of 
mitral valve prolapse, aortic aneurysms and intracranial aneurysms.[29] 
 
Investigations 
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Age banded ultrasound criteria have been established for the diagnosis of ADPKD in 
families with a positive family history.[30] CT and MRI are more sensitive than 
ultrasonography in the detection of cysts but have not been formally evaluated against 
ultrasonography.[31] Genetic testing for PKD1 and PKD2 by direct DNA sequencing 
are now readily available for predictive and diagnostic testing.[32, 33] In a research 
setting, positive detection rates of up to 89% have been reported [34]. Of these, 60-
65% had definite PKD1 mutations, 4% had large deletions/duplications while 20-26% 
were missense changes; in this latter group, it may be difficult to assign pathogenicity 
in the absence of a functional test. Evolutionary conservation, predicted effects on 
secondary structure or splicing, the absence of other pathogenic changes and 
segregation analysis within the pedigree will inform the likelihood whether a 
particular change is pathogenic (but see later). PKD1 is also highly polymorphic 
(average 10 neutral variants per patient) and this complicates the interpretation of any 
changes found [34]. 
 
Predictive testing is indicated in potential live related kidney donors from ADPKD 
families where imaging is negative or equivocal in the under 40 year age group.[35] 
Diagnostic testing is indicated in families with very early-onset disease (under 2 years 
of age) where a very high recurrence rate of (~45%) has been reported [36]. This 
could facilitate pre-implantation genetic diagnosis where indicated. 
 
Some early-onset cases may relate to the co-inheritance of an incompletely penetrant 
or hypomorphic PKD1 allele from the ‘normal’ parent which in combination with an 
inactivating allele, leads to the severe early-onset phenotype [37, 38]. Since the 
penetrance of a single hypomorphic allele is low, segregation may appear as an 
9 
 
apparent ‘de novo’ mutation or recessive (phenocopying ARPKD) inheritance. The 
prevalence of hypomorphic alleles as disease modifiers in early-onset or typical onset 
disease is not known. 
 
The co-inheritance of germline mutations in other cystic disease genes (eg HNF1, 
PKHD1) alongside PKD1 or PKD2 alleles may similarly lead to a more severe renal 
phenotype [39]. The rate of new mutation for PKD1 has been estimated at 4-5% of 
cases though the possibility of mosaicism or non-paternity should be considered in the 
absence of a positive family history [40]. Other diseases that may phenocopy ADPKD 
if present in the carrier state (OFD-1 females) or if other systemic features are mild 
(eg HNF1b, TSC) should form part of the differential diagnosis. 
 
The screening of asymptomatic at risk children is presently not recommended. 
However it has been reported that the prevalence of hypertension (15%), borderline 
hypertension (15%) and microalbuminuria (36%) in children with ADPKD could be 
higher than previously thought [41] and associated with increased left ventricular 
mass in children with borderline hypertension [42]. A reasonable course of action 
would therefore be to monitor at risk children for the development of hypertension 
and proteinuria and institute antihypertensive treatment early. In future, screening 
could be offered at an earlier age once an effective intervention is identified. 
 
Treatment 
The mainstay of treatment is controlling hypertension, reducing proteinuria and 
treating infections. Two recent trials failed to demonstrate an improvement or slower 
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rate of decline of eGFR with mTOR inhibition [43, 44]. Several other interventional 
studies are in progress.[45, 46]. 
 
Prognosis 
Heart disease is the most common cause of death among patients with ADPKD, 
followed by infection and neurological events.[47, 48] Renal function does not 
usually start to decline until the fourth decade.[49]  
 
Nephronophthisis 
Nephronophthisis (NPHP) is an autosomal recessive condition caused by more than 
13 genes  [50]. It has been reported worldwide with an incidence of 9 per 8.3 million 
in the USA and 1 in 50,000 live births in Canada [51]. Clinically, three forms of 
NPHP (infantile, juvenile and adolescent) are recognised based on the age of 
presentation (Table 2). Extra-renal features are present in 10-20% of cases of NPHP 
[52]. A number of syndromes with nephronophthisis and prominent extra-renal 
features associated with mutations in NPHP genes have been described. These include 
Joubert’s syndrome (cerebellar ataxia), Senior-Loken syndrome (tapetoretinal 
degeneration) and Cogan’s syndrome (oculomotor apraxia) [53]. In addition, some 
NPHP genes (NPHP6, 8, 11) can phenocopy the lethal Meckel-Gruber syndrome 
(occipital encephalocele, polydacytyly, enlarged dysplastic kidneys).  
 
Pathophysiology and Histopathology 
On ultrasound, patients with NPHP may have normal or reduced kidney size, 
corticomedullary cysts or loss of corticomedullary differentiation. On renal biopsy, 
tubular atrophy, interstitial fibrosis and changes in the tubular basement membranes 
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(TBM) are prominent features. The TBM is irregularly thickened and often there is an 
abrupt transition between a thick segment and a normal or disintegrated one.[54]. In 
infantile NPHP, there are typically no TBM changes; the features are those of 
moderate renal enlargement with cortical microcysts. [55]  
 
A total of 13 recessive genes (NPHP1-13) have been linked to the NPHP phenotype, 
some in single families; these account for less than 30% of all patients indicating that 
the majority of NPHP genes are yet to be discovered [56]. In a world-wide cohort of 
365 NPHP families, NPHP1 mutations were the most frequent and accounted for 64% 
of all identified alleles [50]. The identification of these genes has led to the 
recognition that mutations in some ‘NPHP’ genes (eg NPHP 6, 8, 11, 12) can give rise 
to both mild (NPHP), intermediate (Joubert’s syndrome, JBTS) and severe (Meckel-
Gruber syndrome, MKS) phenotypes. The genetic mechanisms determining 
phenotype are complex with evidence of gene locus heterogeneity, allelic effects 
(NPHP6) and modifier genes, all of which interact to determine disease severity and 
the extent of extrarenal involvement [50]. 
 
A common finding in NPHP proteins is their localisation to primary cilia or 
centrosomes [57]. Mutations in these genes therefore impair ciliary function both in 
renal tubular epithelial cells and in other organs.[52] Some NPHP proteins (NPHP1, 2, 
4, 10) also localise to cell-cell junctions or focal adhesions (NPHP1) where they 
regulate junction integrity and polarity [58-60]. In some cells, distinct ciliary sub-
compartment localisation has been reported for different NPHP proteins [61]. Of 
interest, NPHP1 has also been reported to bind polycystin-1 and may regulate 
apoptosis [62]. 
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The NPHP proteins do not share a high degree of sequence homology but rather form 
interacting protein complexes which function in distinct pathways or subcellular 
compartments. A recent study has shown that the NPHP proteins co-purify in at least 
3 separate protein complexes with distinct subcellular locations and functions [63]. 
NPHP1, 4 and 8 are present in the transition zone of primary cilia and regulate apical 
junction formation, NPHP 5 and 6 are located at the centrosomes and regulate 
ciliogenesis whereas the MKS proteins, MKS1 and MKS6 regulate hedgehog 
signalling. NPHP2/INVS and the JBTS3/AHI1 protein, Jouberin act as molecular 
bridges between the three modules. These findings provide a molecular link between 
NPHP, JBTS and MKS and an explanation for the overlapping spectrum seen in these 
diseases. However, the proteins that make up the transition zone could vary between 
cell types and organisms [61, 64-66]. 
 
Clinical Presentation  
Juvenile nephronophthisis (ESRD ≥ 4yr) is the most common form of NPHP and the 
usual age at which NPHP presents (except for NPHP2/INVS). The first symptoms 
usually develop at 4-6 years of age. Reduced urinary concentrating capacity and 
increased urinary sodium loss leads to polyuria, polydipsia, enuresis and dehydration. 
Chronic dehydration and eventually renal insufficiency causes growth retardation and 
failure to thrive [52]. Due to the mild nature of the initial symptoms, there can often 
be a delay in diagnosis. As there is salt wasting, blood pressure does not tend to be 
raised until individuals develop renal failure. A normochromic, normocytic anaemia is 
common and may occur prior to renal insufficiency. [67] ESRD occurs at a mean age 
of 13 years. [68] 
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The adolescent form was described after identification of the NPHP3 gene in a large 
Venezuelan family. ESRD occurred at a mean age of 19.[69] However the 
histological features are very similar to the juvenile form and often they are regarded 
as part of the same disease. The age of ESRD in NPHP3 appears more variable than 
other forms of NPHP, ranging between 3 to 13 yrs. 
 
Infantile NPHP (ESRD ≤ 4yr) is usually caused by mutations in NPHP2/INVS 
although patients with other NPHP mutations can present with infantile ESRD [50, 
70]. Situs inversus and ventricular septal defects are commonly associated with 
NPHP2 [52].  
 
Investigations 
Urinalysis shows low specific gravity in early morning samples. Careful 
ophthalmoscopy should be performed and an MRI to look at the cerebellum if 
neurological symptoms are present [53]. 
 
Genetic testing is possible in many cases, negating the need for renal biopsy. 
Screening for gene mutations can be guided by the age of presentation and the 
presence or absence of specific extra-renal features.[50, 52] Asymptomatic siblings 
are screened for urinary concentrating defects and abnormalities on USS rather than 
undergoing genetic testing. 
 
Treatment 
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There is no specific treatment. NPHP does not recur in the transplanted kidney. Live 
related heterozygous carriers can donate.  
 
Prognosis 
The prognosis depends on the age of presentation and whether there are extra-renal 
features.  
 
Medullary Cystic Kidney Disease 
Medullary cystic kidney disease (MCKD) is a rare autosomal dominant condition 
leading to ESRD. It generally presents in adulthood but can occur in children.[71] It 
was once thought to be the same disease entity as juvenile NPHP due to the 
overlapping phenotypes.[72] The condition is caused by mutations in several 
genes.[73, 74] The MCKD1 locus has been mapped to chromosome 1q21 but the gene 
has yet to be identified. The MCKD2 locus on chromosome 16p12 has been identified 
as the UMOD gene [74].   
 
Recently, it was proposed that MCKD be reclassified as one of four types of 
autosomal dominant interstitial kidney disease (ADIKD) based on the underlying 
gene mutation: (1) UMOD: mutations in UMOD are the most common and can 
present as MCKD2, familial juvenile hyperuricemic nephropathy (FJHN), 
uromodulin-associated kidney disease (UAKD) and glomerulocystic kidney disease 
(GCKD); (2) REN: mutations in REN, which encodes renin, have been identified in a 
few ADIKD families [75]; (3) Chromosome 1q21: also known as MCKD1; (4) 
Unidentified genes: some families without UMOD or REN mutations and unlinked to 
chromosome 1 have been reported [76]. This classification does not require the 
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presence of cysts for diagnosis and reflects the highly variable cystic phenotype in 
ADIKD which is most prominently expressed as MCKD. 
 
Pathophysiology and Histopathology 
MCKD1 
Renal biopsy shows tubular atrophy, interstitial fibrosis, lymphocytic infiltration, 
splitting or lamellation of the thickened and irregular tubular basement membranes 
[77]. The glomerular basement membranes are usually unaffected though glomerular 
sclerosis can occur. 
 
MCKD2 
The UMOD gene on chromosome 16p12 encodes for uromodulin, the most abundant 
protein found in normal human urine and which is expressed specifically in the thick 
ascending loop of Henle. Its functions are not well understood but it is thought to 
maintain the watertight properties of the thick ascending loop of Henle and/or protect 
against UTIs.[78, 79] Mutant uromodulin accumulates in the endoplasmic reticulum 
leading to tubular cell atrophy and death.[80] One study has reported uromodulin 
expression in primary cilia and centrosomes. [81] UMOD mutations are associated 
with hyperuricaemia and early-onset gout: FJHN is allelic to MCKD2. On biopsy, 
diffuse tubulointerstitial fibrosis is prominent with occasional tubular dilatations or 
cysts [82]. 
 
Clinical Presentation  
MCKD1 
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The clinical picture of MCKD1 is that of a slowly progressive chronic kidney disease. 
There is minimal proteinuria and haematuria. Hypertension becomes more common as 
the kidney disease progresses, as does hyperuricaemia.[77] The course of the disease 
is variable with ESRD occurring between 25 and 55 years of age.[77, 83] 
 
MCKD2 
Hyperuricaemia is characteristic of MCKD2. In females, this is often asymptomatic 
but commonly presents as gout in teenage males.[84] As with MCKD1, progressive 
renal impairment occurs. Hypertension can occur but proteinuria is minimal. Mild 
concentrating defects can also occur [85].  
 
Investigations 
MCKD1 
The absence of significant proteinuria in a patient with renal impairment and a strong 
family history should be enough to consider MCKD. Cysts are sometimes seen on 
ultrasound but are not essential for the diagnosis.[77] Renal biopsy can be performed 
but the findings are non-specific.[86] A definitive diagnosis can be made through 
linkage analysis if there is linkage to chromosome 1q21. 
 
MCKD2 
As with MCKD1, diagnosis often relies on clinical suspicion. Patients with MCKD 2 
often have hyperuricaemia. Medullary cysts may be seen on ultrasound. The biopsy 
findings are non-specific. Mutational analysis of the UMOD gene can confirm the 
diagnosis. 
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Treatment 
MCKD1 
Treatment is mainly supportive. The disease does not recur in the transplanted kidney 
but family members need to be screened if they come forward as live donors. 
 
MCKD2 
The management of MCKD2 is the same as MCKD1 except for the possible benefits 
of allopurinol. Allopurinol can be used to prevent gout but there is conflicting 
evidence as to whether early allopurinol therapy can also prevent progression to 
ESRD. [82, 84, 87] 
 
Prognosis 
The age of progression to ESRD varies between 20 and 70 years of age. 
 
Hepatocyte Nuclear Factor 1-beta (HNF1β) Mutations 
Mutations of HNF1β were first identified as a rare cause of maturity-onset diabetes of 
the young type 5 (MODY5).[88] It is now recognised that HNF1β mutations are 
responsible for a range of different renal abnormalities including cystic diseases. The 
HNF1β gene is located on chromosome 17q12. 
 
Pathophysiology and Histopathology 
HNF1β is a member of the homeodomain-containing superfamily of transcription 
factors. It encodes the transcription factor 2 (TCF2) and functions as a homodimer or 
heterodimer with HNF1α.[89] HNF1β appears to be a master regulator controlling the 
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transcription of multiple cystic genes including PKHD1, PKD2, UMOD and 
Tg737/polaris.[90] 
 
The pleiotropic features of HNF1β mutations can be explained by its role in the 
development of pancreas, kidney, liver, lung and gut and expression in the neural tube 
and genital tract.[91, 92] In the embryonic kidney, HNF1β is expressed in the ureteric 
bud, the comma and s-shaped bodies and in the proximal and distal tubules [91] 
Although it is not expressed in glomeruli, glomerulocystic kidney disease has been 
associated with HNF1β mutations (see later). It has been suggested that the formation 
of glomerular cysts could result from transient obstruction of immature nephrons.[93]  
 
Several studies have not found a clear genotype-phenotype correlation between the 
type of mutation and the severity and/or type of renal disease. There is strong 
intrafamilial variability suggesting that non-allelic or environmental factors must be 
important.[89, 94] Mutations may involve heterozygous deletion of the whole gene or 
small mutations including missense, nonsense, frameshift and splice site mutations. In 
the studies to date, de novo mutations accounted for a third to half of all cases.[88, 94] 
 
Clinical Phenotypes 
Renal cysts are present in most HNF1β carriers, including some with glomerulocystic 
kidney disease (GCKD). Renal malformations are also common eg single and 
horseshoe kidneys.[89, 94] HNF1β mutations have been identified in all cases of 
familial hypoplastic glomerulocystic kidney disease examined so far. This condition is 
inherited in an autosomal dominant fashion.[93] Not all individuals with HNF1β 
mutations have diabetes but renal cysts and diabetes (RCAD) is a common 
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phenotype.[94] Prenatally, bilateral hyperechogenic kidneys of normal or moderately 
enlarged size is the most frequent finding. Other prenatal phenotypes include bilateral 
multicystic kidney disease (MCD), unilateral MCD, unilateral renal agenesis, 
unilateral renal hypoplasia, renal macrocysts and isolated upper urinary tract dilation. 
All patients with unilateral MCD developed postnatal abnormalities in the 
contralateral kidney.[89] The degree of renal impairment varies widely with some 
cases of ESRD presenting in childhood or prenatally but other adult cases with normal 
renal function.  
 
Other features of HNF1β mutations include early onset gout and/or hyperuricaemia, 
genital tract malformations, pancreatic atrophy, abnormal liver function tests and 
hypomagnesaemia. [89, 93]. The underlying pathogenesis of hyperuricemia in some 
patients is unknown though rarely, it may phenocopy FJHN (see above) [95]. In a 
seminal study, hypomagnesemia was found in 44% of children with HNF1β mutations 
[96] and was associated with urinary magnesium wasting and hypocalciuria in a 
subset of patients. The likely pathogenesis of this abnormality is a defect in HNF1β 
mediated transcription of FXYD2, which encodes the  subunit of Na+-K+-ATPase; 
mutations in FYXD2 are associated with autosomal dominant hypomagnesemia and 
hypocalciuria [97]. 
 
Investigations 
HNF1β mutations should be considered in all individuals with an unidentified cause 
of cystic kidney disease. Since a significant proportion of mutations are de novo, the 
absence of a family history should not preclude genetic testing. 
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Treatment 
The treatment is dependent on the degree of renal impairment and the presence of 
other features such as diabetes.  
 
Prognosis 
The prognosis varies widely and is difficult to predict. Genetic counselling is also 
challenging due to the lack of phenotype-genotype correlation. 
 
Glomerulocystic Kidney 
The term glomerulocystic kidney (GCK) refers to a kidney with more than 5% cystic 
glomeruli.[98] Lennerz proposed a useful classification system and suggested that the 
term glomerulocystic kidney disease (GCKD) is used for the familial subtypes 
only.[99] 
 
Type I: GCK in PKD 
Early onset ADPKD sometimes presents as GCK. 
 
Type II: Hereditary GCK (GCKD) 
GCKD includes autosomal dominant GCKD (ADGCKD) due to UMOD mutations, 
familial hypoplastic GCKD due to HNF1β mutations and GCKD due to mutations 
that have not yet been classified. 
 
Type III: Syndromic GCK 
Syndromic GCK is when GCK occurs as part of a known syndrome without dysplasia, 
the most common being tuberous sclerosis. Other examples include Zellweger 
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cerebrohepatorenal syndrome, von Hippel Lindau disease and X-linked dominant 
oral-facial-digital syndrome type 1 (OFD-1). 
 
Type IV: Obstructive GCK 
Obstructive GCK is GCK associated with renal dysplasia or urinary obstruction 
without dysplasia and no evidence of a heritable condition. It is a common cause of 
GCK.  
 
Type V: Sporadic GCK 
Included in this category are ischaemic GCK and drug induced GCK. The ischaemic 
causes are often due to systemic sclerosis or haemolytic uraemic syndrome. Lithium is 
a recognised cause of drug-induced GCK. 
 
Pathophysiology and Histopathology 
Glomerular cysts are defined as Bowman space dilatation of more than 2 to 3 times 
the normal size.[98] Glomerular tufts help to distinguish glomerular cysts from cysts 
of tubular origin but may be absent if the tufts degenerate. [99] The pathogenesis of 
GCK is unknown although a number of theories have been proposed.[99] There is 
some evidence that primary cilia dysfunction may be involved.[100] 
 
Clinical Presentation  
The presentation of GCK varies. Infants may present with an abdominal mass or renal 
insufficiency. In later childhood or in adulthood, the presentation may be with 
haematuria, hypertension or abdominal pain. In cases of syndromic GCK, patients are 
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likely to present with other features. UTIs may precede diagnosis of GCK in 
obstructive causes. 
 
Investigations 
GCK is not easy to diagnose by ultrasound in the foetus or neonate. It is difficult to 
distinguish GCK from other cystic renal conditions.[101] In adults, glomerular cysts 
are often missed by ultrasound or CT. MRI is much more reliable.[102] Renal biopsy 
may be necessary to distinguish GCK from tubular cystic disease. Genetic testing is 
possible for certain subtypes of GCK.  
 
Treatment 
The treatment will depend on the underlying cause of GCK. Most treatments will be 
symptomatic. 
 
Prognosis 
The prognosis is variable and depends on the underlying cause of GCK and the rate of 
decline in renal function. 
 
The ciliary hypothesis and cystic disease 
Primary cilia as sensory organelles 
Primary cilia are hair-like organelles expressed by almost every cell and tissue in the 
body [103]. Unlike motile cilia, primary cilia are generally non-motile though they are 
sensitive to bending or flow [104]. Sensory cilia involved in vision and smell are 
modified primary cilia showing that they can sense visual and olfactory stimuli. 
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In non-dividing polarised epithelial cells, cilia extend as apical structures consisting of 
a microtubule core enveloped by a membrane lipid bilayer. Ultrastructurally, all cilia 
can be classified as ‘9+2’ (motile) or ‘9+0’ (primary) depending on the presence or 
absence of a central pair of microtubules. Prior to entering mitosis, cilia are resorbed 
and both centrosomes form the mitotic spindle poles. As cells become quiescent, cilia 
reform. More recently, ciliary sub-compartments have been described associated with 
specific locations of different proteins (Figure 1A).  
 
Cilia, flagella and intraflagellar transport 
Evolutionarily, cilia are structurally related to (motile) flagella expressed by single 
cell organisms such as the green algae, Chlamydomonas reinhardtii. Remarkably, 
proteins involved in the formation and maintenance of flagella structure, a 
microtubule-dependent process called intraflagellar transport (IFT) are highly 
conserved throughout evolution, being also expressed in mammalian cilia [27]. IFT is 
essential for the assembly, disassembly and maintenance of cilia. In brief, an IFT-B 
complex (at least 15 proteins) is transported from the cilia base to the cilia tip through 
the action of the microtubular motor protein kinesin. An IFT-A complex (6 proteins) 
is transported from the ciliary tip to the base through the action of dynein (Figure 1A).  
 
Mutations in human IFT proteins have been associated with several skeletal dysplasia 
syndromes such as Sensenbrenner syndrome (cranioectodermal dysplasia, MIM 
218330), Jeune syndrome (asphyxiating thoracic dysplasia, MIM 611263) and short-
rib polydactyly (MIM263510). Mutations in two IFT-A proteins (IFT139, 144) 
syndrome have been reported with in patients with isolated nephronopthisis (NPHP12, 
13) indicating a phenotypic overlap between Sensenbrenner syndrome and NPHP. 
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Cilia, centrosomes and the cell cycle 
The link between cilia and cystic disease came from several co-incidental findings 
[28]. Since these seminal discoveries, many more proteins associated with a cystic 
kidney phenotype have been localised to primary cilia and their associated structures, 
the centrosomes. This has led to the formulation of the ‘ciliary hypothesis’ as a 
unifying pathogenic mechanism for cyst formation [27]. A link to cell cycle control is 
also implied by the fact that the mother centriole (or basal body) enucleates the 
primary cilium (present in non-dividing cells) and that both centrioles also form the 
mitotic spindle poles (in dividing cells). Some cystoproteins remain localised at the 
spindle poles during mitosis. These cilia-associated diseases have been termed 
‘ciliopathies’ [57]. 
 
Cilia signalling in extrarenal tissues 
Abnormalities in cilia structure or function could explain some of the unusual 
extrarenal features reported in some of these diseases such as situs inversus, retinitis 
pigmentosa, skeletal or digital abnormalities and CNS malformations.  
 
Left-right patterning of the body axis is determined by the function of nodal cilia 
which are motile and transmit an asymmetric Ca2+ signal. The findings of situs 
inversus in Pkd2 null mice [105] and in several other ciliopathy mutants (eg 
nphp2/invs) indicated that a more general abnormality in cilia function could explain 
the systemic features of the ciliopathies. In the retina, the connecting cilium represents 
a modified transition zone which controls the transport of rhodopsin containing 
vesicles between the inner and outer photoreceptor segments. The finding of retinitis 
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pigmentosa in many ciliopathies correlates with their localisation to this structure. 
Finally, a clear link between hedgehog signalling, a key developmental signalling 
pathway, and primary cilia signalling has been shown in mouse models [106]. 
Abnormalities in hedgehog signalling probably underlie the digital and CNS 
abnormalities seen in some of the ciliopathies. Other signalling pathways that have 
been linked to primary cilia are the Wingless (Wnt) and Notch pathways, cAMP/PKA, 
PDGF-, somatostatin receptor 3 (SSTR3) and mTOR kinase (Figure 1A). Although 
these are not associated with discrete phenotypes and may vary between tissues, they 
do indicate that a variety of ligand-gated receptors can signal through cilia. 
 
Cilia signalling in the kidney 
How abnormalities in cilia or centrosome function lead to renal cysts is still unclear. 
Apart from intercalated cells, it is thought that all renal cells throughout the nephron 
express primary cilia. Motile (9+2) cilia are expressed in the pronephros of lower 
vertebrates and have been occasionally detected in human kidney [107, 108]. In the 
latter, they could represent a recapitulation to an embryonic phenotype or a 
dedifferentiation phenotype to injury. 
 
Planar cell polarity (PCP) and oriented cell division (OCD) are two key processes that 
are critical for maintaining tubular diameter during tubular elongation in development 
or repair following injury. Renal epithelial cell cilia are sensitive to flow [104]. 
Defects in OCD have been reported in several cystic mouse mutants linked to cilia 
structure (Kif3a) or function (HNF1b) [109, 110]. The non-canonical Wnt pathway is 
likely to be important in PCP regulation in the kidney [111] and the switch between 
the two limbs of Wnt signalling mediated through primary cilia flow sensing [112]. 
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Pkd1 mutant tubular cells have defects in cilia-mediated flow-induced Ca2+ signalling 
[113]. There is conflicting evidence as to whether abnormalities in OCD or PCP are 
critical to the onset of cyst formation in ADPKD or ARPKD [114, 115].  
 
Non-ciliary mutants and renal cysts 
It is helpful to consider that in the vast majority of the ciliopathies, renal cysts are rare 
unless associated with organ dysplasia (Meckel’s) or of late-onset when associated 
with degeneration (NPHP). These phenotypes appear distinct from those of more 
‘classical’ cystic diseases such as ADPKD and ARPKD, even though these are 
included in the ciliopathies. This could mean either that the ADPKD or ARPKD 
proteins serve more distinct ciliary functions (from the other ciliopathy proteins) or 
that their non-ciliary functions may be more important in preventing cyst formation. 
In this regard, it is worth noting that polycystin proteins are also prominently 
expressed at the basolateral membrane in epithelial cells (where they may regulate 
cell adhesion) and that polycystin-2 can also function as an ER located Ca2+ release 
channel. [25] We cannot easily differentiate the relative importance of ciliary and 
non-ciliary functions of the two proteins at present. Similarly, several of the NPHP 
genes (NPHP1, 2, 4, 10) are clearly expressed at the basolateral epithelial membrane 
where they could regulate epithelial morphogenesis independent of their cilia function.  
 
Other cystogenic proteins that have exclusive non-ciliary locations are the ER proteins, 
Sec63 (MIM 608648) and PRKCSH (MIM 177060), which are associated with 
autosomal dominant polycystic liver disease (ADPLD), the mitochondrial protein 
XPNPEP3 (MIM 613553) which is associated with a nephronopthisis-like phenotype 
(NPHP-L1) with occasional cysts, the basement membrane proteins, Laminin 5 
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(LAMA5, MIM 608648) and collagen IV1 (COL4A1, MIM 601033) which when 
mutated, can be associated with renal cysts [6]. 
 
These observations suggest two possibilities. First, normal ciliary structure or function 
is essential in the pathogenesis of all cystic diseases and that even ‘non-ciliary’ 
cystogenic proteins may somehow interfere with the processing, trafficking or 
function of key ciliary mediators. An alternative explanation is that there are both 
ciliary and non-ciliary pathways involved in the pathogenesis of cysts. 
 
 
Conclusions 
Mutations in genes that affect ciliary structure or function are increasingly recognised 
as an important group of diseases (the ciliopathies). Nonetheless, they are highly 
heterogenous and it may be helpful to think of a phenotypic spectrum ranging from 
dysplasia to degeneration or cystic change (Figure 1B). The occasional phenotypic 
overlap between NPHP, JBTS and MKS illustrates this well. The mechanistic link 
between cilia dysfunction and cystic transformation in the kidney remains to be fully 
elucidated. 
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Figure legends 
Figure 1  
(A) Cilia structure and signalling. Primary cilia extend as apical structures with a 
microtubular core in polarised kidney epithelial cells. They are assembled, 
disassembled and mainatained by a process called intraflagellar transport (IFT). 
Complex B proteins undergo anterograde transport and complex A undergo retrograde 
transport. The transition zone (orange) and inversin (green) ciliary sub-compartments 
are shown. Cilia signalling can be activated by mechanical bending or flow or ligand 
binding to a variety of membrane receptors expressed in the ciliary membrane. Cilia 
signalling can be usefully divided into Ca2+ or non- Ca2+ mediated pathways. Apart 
from stimulating Ca2+ release from intracellular stores, Ca2+ increases could activate 
protein kinase C (PKC), protein kinase A (PKA) and phospholipase C (PLC) 
signalling. Non- Ca2+ signalling could involve multiple receptors including 
developmental pathways such as Hedgehog, Wnt and Notch, as well as those 
regulating cell division or cell size such as PDGF-platelet-derived growth factor- 
alpha), SSTR3 (somatostatin receptor 3) or mTOR (mammalian target of rapamycin). 
 
(B) Disease spectrum of the ciliopathies. The phenotypic spectrum of the ciliopathies 
may overlap and ranges from organ dysplasia, degeneration or fibrosis to cystic 
change. A number of the common ciliopathies and their typical phenotypes are shown 
on the diagram. 
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Table 1 Diseases commonly associated with a cystic phenotype 
 
MIM 
Gene/locus
number 
Disease Inheritance, 
genes 
Incidence. 
Male; Female 
Age at 
presentation 
Renal features Extra-renal features 
Genetic Disorders 
*606702 Autosomal 
Recessive 
Polycystic 
Kidney Disease 
A.R. PKHD1 
(6p21.1-p12) 
1 in 20,000 
(gene frequency 
1 in 70) 
M:F 1:1 
Neonatal, 
childhood. 
Abdominal masses, 
polyuria, polydipsia, 
UTIs, ESRD. 
Oligohydramnios if severe, 
hypertension, ascending 
cholangitis. 
*601313 Autosomal 
Dominant 
Polycystic 
Kidney Disease 
A.D. PKD1 
(16p13.3-
p13.12), PKD2 
(4q21-q23) 
1 in 400-1 in 
1000 
M:F 1:1 but 
renal phenotype 
may be more 
severe in males 
Usually 20-
40 years. 
Clinical findings in 
children rare. In adults- 
abdominal pain, UTIs, 
ESRD. 
Clinical findings in children 
rare. In adults- hypertension, 
sub-arachnoid haemorrhage. 
*607100 
*243305 
*608002 
*607215 
*609237 
*610142 
*608539 
*610937 
*609799 
*609884 
*613524 
*612014 
*614377 
Nephronophthisis A.R. 13 
causative genes 
NPHP1-13  
1 in 50,000 
M:F 1:1 
3 forms. 
Infancy, 
childhood, 
adolescence 
Polyuria, polydipsia, 
enuresis, ESRD.  
Growth retardation, anaemia, 
(visual loss, liver fibrosis, 
cerebellar ataxia if associated 
with another syndrome). 
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%174000, 
*191845 
Medullary Cystic 
Kidney Disease 
A.D. MCKD1, 
MCKD2/UMOD
Rare. 
M:F 1:1 
Early 
adulthood 
Clinical findings in 
children rare. In adults-
ESRD 
Clinical findings in children 
rare-may develop gout. In 
adults-gout. 
*189907 HNF1β-related 
diseases 
HNF1β (17q12) ? 
M:F 1:1 
Any age Highly variable. 
Hyperechogenic 
kidneys, multicystic 
kidney disease, renal 
agenesis, renal 
hypoplasia, cystic 
dysplasia, or 
hyperuricaemic 
tubulointerstitial 
nephropathy not 
associated with UMOD 
mutation[89] 
Congenital anomalies of the 
urinary tract, pancreas 
atrophy, liver abnormalities, 
maturity-onset diabetes of the 
young type 5 and genital 
malformations. 
*608537 Von Hippel-
Lindau Disease 
A.D. VHL 
(3p25.3) 
1 in 36,000 
M:F 1:1 
Childhood, 
adolescence 
or adulthood. 
Mean age 26. 
Renal symptoms rare 
during childhood. 
Adults-renal cysts, renal 
cell carcinoma (RCC).  
Clinical findings in children 
rare. In adults- CNS 
haemangioblastomas, retinal 
haemangioblastomas, 
phaeochromocytoma, 
pancreatic cysts. 
*605284 
*191092 
Tuberous 
Sclerosis 
Complex 
A.D. High rate 
of spontaneous 
mutations. TSC1 
(9q34), TSC2 
(16p13.3) 
1 in 1000 
M:F 1:1 but 
female 
morbidity and 
mortality rates 
higher 
Childhood Renal symptoms rare 
during childhood. Renal 
angiomyolipomas, renal 
cysts, ESRD. 
Numerous systemic findings. 
Facial angiofibromas, cardiac 
rhabdomyomas, 
lymphangioleiomyomatosis, 
retinal hamartomas.  
 Renal Cysts in 
Malformative 
Varies according to syndrome (including Meckel-Gruber, Ehlers-Danlos, Trisomy 13,18 and 21, and Zellweger 
syndromes). 
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syndromes  
Non-genetic disorders-developmental 
 Medullary 
Sponge Kidney 
Mutations in 
GDNF have 
been linked. 
May be part of 
other 
syndromes.  
1 in 2000-20,000 
M:F 1:1 (but 
may be more 
severe in 
females) 
20-50yr but 
may present 
younger. 
Haematuria, UTI, 
calculi. 
 
 Multicystic Renal 
Dysplasia 
Usually 
sporadic but 
familial disease 
has occurred 
(PAX 2). Also 
associated with 
many 
syndromes. 
1 in 4000 
M:F 2:1 
Usually 
detected pre-
natally or 
soon after 
birth 
Abdominal mass, flank 
pain, UTI. 
Hypertension 
Non-genetic disorders-acquired 
 Acquired Renal 
Cystic Disease 
Acquired 7-22% of pre-
dialysis 
patients. >90% 
10 years post 
dialysis. 
Any age 
depending on 
age of 
development 
of ESRD. 
Flank pain, bleeding, 
RCC. 
 
 Simple Renal 
Cysts 
Acquired Very common. 
Incidence 
increases with 
age. 
M:F 2:1 
Any age. 
Usually 
incidental 
finding. 
Clinical findings rare 
especially in children. In 
adults - pain, bleeding, 
infection.  
Clinical findings rare 
especially in children. 
 Multilocular 
Renal Cysts 
Acquired Rare Any age but 
often early 
Often asymptomatic. 
Can present with 
Hypertension 
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childhood abdominal mass, 
abdominal pain or 
haematuria 
 Hypokalaemic 
renal cysts 
Acquired  Any age. Usually cysts do not 
cause symptoms. 
 
Genetic and non-genetic forms 
 Glomerulocystic Kidney 
 GCK in PKD ADPKD and 
ARPKD 
M:F 1:1.  Any age As per primary disease As per primary disease 
Hereditary 
GCKD  
 
ADGCKD and 
HNF1β 
mutations 
M:F 1:1  Any age. Abdominal masses, 
renal insufficiency, 
flank pain, haematuria. 
Hypertension 
Syndromic GCK As per 
syndrome 
As per syndrome Any age As per syndromes e.g. 
X-linked dominant oral-
facial-digital syndrome 
type 1, tuberous 
sclerosis 
 
Obstructive GCK   Any age Associated with renal 
dysplasia. Urinary tract 
infections. 
 
Sporadic GCK May be a de 
novo mutation, 
ischaemic or 
drug induced. 
 Any age Abdominal masses, 
renal insufficiency, 
flank pain, haematuria. 
Described post 
haemolytic uraemic 
syndrome[116] 
Hypertension 
 
 
MIM = Mendelian Inheritance of Man; AD = autosomal dominant, AR = autosomal recessive.
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Table 2 Cystoproteins and their putative functions 
 
Disease Gene Protein  Localisation Function 
Autosomal Recessive 
Polycystic Kidney 
Disease 
PKHD1 Fibrocystin/ 
polyductin 
6p21.1-p12 Exact function 
unknown. Expressed 
in apical membrane, 
primary cilia and 
centrosomes. Interacts 
with polycystin-2. 
Autosomal Dominant 
Polycystic Kidney 
Disease 
PKD1 Polycystin-1 16p13.3-p13.12 Mechanosensitive or 
ligand-activated 
receptor; functionally 
complexed with 
polycystin-2. 
Expressed in 
basolateral plasma 
membrane, cilia, 
centrosomes.  
PKD2 Polycystin-2 4q21-q23 A non-selective Ca2+ 
channel. Functionally 
complexed with 
polycystin-1. 
Expressed in ER, 
basolateral plasma 
membrane, cilia, 
centrosomes. 
Nephronophthisis 
Infantile, 
Juvenile/Adolescent 
NPHP1/SLSN1 (J) Nephrocystin 1 2q13 Involved in primary 
cilia function and the 
cell cycle. Some 
NPHP2/INVS (I) Inversin 9q31.1 
NPHP3/SLSN3 (I,J,A) Nephrocystin 3 3q22.1 
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(I/J/A) NPHP4/SLSN4 (J) Nephrocystin 4 1p36.31 localise to cell-cell 
junctions (1, 2, 4, 10) 
or focal adhesions (1). 
NPHP5/IQCB1/SLSN5 (J) Nephrocystin 5 3q13.33 
NPHP6/CEP290/LCA10/SLSN6/JBTS5/MKS4 
(J) 
Nephrocystin 6 12q21.32 
NPHP7/GLIS2 (J) GLIS 2 protein 16p13.3 
NPHP8/RPGRIP1L/JBTS7/MKS5 (I,J) Nephrocystin 8 16q12.2 
NPHP9/NEK8 (I/J) Nephrocystin 9 17q11.2 
NPHP10/SLSN7/SDCCAG8 (J) Centrosome Colon 
Cancer Autoantigen 
Protein (CCCAP) 
1q43 
NPHP11/MKS3/TMEM67 (J) Meckelin 8q22.1 
NPHP12/TTC21B/JBTS11 (I,J) IFT139 2q24.3 
 NPHP13/WDR19 (A) IFT144 4p14  
Medullary Cystic 
Kidney Disease 
MCKD1  1q21 Not known 
MCKD2 (UMOD) Uromodulin 16p12 Possible role in 
maintaining integrity 
of thick ascending 
loop of Henle. 
Localisation to cilia 
and centrosomes. 
HNF1β/TCF2 range HNF1β HNF1β protein or 
Transcription Factor 
2 (TCF2) 
17q12 Regulates the 
transcription of 
several key cystic 
genes. 
Von Hippel Lindau 
Disease 
VHL VHL protein 3p26-p25 Tumour suppressor 
gene acting through 
HIF and non-HIF 
dependent pathways. 
Localisation to cilia 
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and role in cilia 
length. [117] 
Tuberous Sclerosis 
Complex 
TSC1 Hamartin 9q34 Complexes with 
tuberin to inhibit 
mammalian target of 
mTOR. [118] 
TSC2 Tuberin 16p13.3 Complexes with 
hamartin. Localises to 
primary cilia and 
regulates cilia length 
[119] 
 
 
I = infantile, J = juvenile, A = adolescent 
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Questions 
1. The PKHD1 gene found on chromosome 6p21 encodes for 
a. Polycystin 
b. Fibrocystin 
c. Inversin 
d. Nephrocystin 1 
e. Neurofibromin 
 
2. Hepatic involvement is associated with 
a. HNF1β mutations 
b. ARPKD 
c. Nephronpohthisis 
d. Medullary sponge kidney 
e. All of above 
 
3. Individuals with juvenile nephronophthisis 
a. Generally have enlarged kidneys 
b. Have glomerular cysts 
c. Usually have tubular cell hypertrophy on renal biopsy 
Key Summary Points 
1. Cystic kidney disease can be genetic, developmental or 
acquired. 
2. Many genetic cystic diseases have been termed 
ciliopathies due to the colocalisation of multiple 
cystoproteins in primary cilia.  
3. The age at presentation and clinical features are wide-
ranging. 
4. Many cystic kidney diseases have extra-renal features or 
form part of a syndrome. 
5. The mainstay of treatment at present is the management 
of the complications of renal impairment. 
Key Research Points 
1. Two negative trials of mTOR inhibitors in ADPKD were 
recently reported. 
2. Other interventional studies are looking at V2 receptor 
antagonists, somatostatin, renin-angiotensin system 
blockade and statin use in slowing cyst development in 
ADPKD. 
3. The function of the primary cilium and its dysfunction in 
disease remains a focus of intense research 
investigation. 
d. Usually have an irregularly thickened tubular basement membrane 
on biopsy 
e. Rarely present before 10 years of age 
 
4. The following condition is never inherited in an autosomal dominant 
fashion 
a. Tuberous sclerosis complex 
b. Medullary cystic kidney disease 
c. Von Hippel Lindau disease 
d. Nephronophthisis 
e. Hereditary glomerulocystic kidney disease 
 
5. The HNF1β gene is located on  
a. Chromosome 13 
b. Chromosome 14 
c. Chromosome 15 
d. Chromosome 16 
e. Chromosome 17 
 
6. Multicystic dysplastic kidney 
a. More commonly affects the left kidney 
b. Is more common in girls 
c. Is usually bilateral 
d. Is rarely detected ante-natally 
e. Is usually diagnosed by biopsy 
 
7. Familial hypoplastic glomerulocystic kidney disease is associated with 
mutations of 
a. MCKD2 
b. HNF1β  
c. TSC1 
d. TSC2 
e. NPHP1 
 
8. Early onset gout is a feature of 
a. ADPKD 
b. ARPKD 
c. Nephronopthisis 
d. Medullary cystic kidney disease 
e. Acquired cystic kidney disease 
 
9. The incidence of autosomal recessive polycystic kidney disease is 
approximately 
a. 1 in 5000 live births 
b. 1 in 20,000 live births 
c. 1 in 40,000 live births 
d. 1 in 80,000 live births 
e. 1 in 100,000 live births 
 
10.  Polyuria and polydipsia are often present in 
a. Autosomal recessive polycystic kidney disease 
b. Juvenile nephronophthisis 
c. Medullary sponge kidney 
d. a,b and c 
e. None of above 
 
Answers 
1b, 2e, 3d, 4d, 5e, 6a, 7b, 8d, 9b, 10d 
Transition zone
Inv compartment
Basal body
FLOW LIGAND
Ca2+ Non-Ca2+
Hedgehog
Wnt/Rho
Notch
RTK (PDGF)
GPCR (SSTR3)
mTOR
PKC
PKA
PLC
Apical
membrane
IFT-B
IFT-A
A
Dysplasia Degeneration
Cysts
MKS JBTS NPHP
ARPKD
ADPKD
BBS
SLSN
MCKD
OFD-1
JATD
B
